Fulcrum Therapeutics Inc (FULC) concluded trading on Wednesday at a closing price of $6.36, with 0.39 million shares of worth about $2.48 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 60.61% during that period and on June 18, 2025 the price saw a loss of about -1.09%. Currently the company’s common shares owned by public are about 53.98M shares, out of which, 47.85M shares are available for trading.
Stock saw a price change of -6.88% in past 5 days and over the past one month there was a price change of -8.23%. Year-to-date (YTD), FULC shares are showing a performance of 35.32% which decreased to -14.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.32 but also hit the highest price of $10.13 during that period. The average intraday trading volume for Fulcrum Therapeutics Inc shares is 551.31K. The stock is currently trading -6.10% below its 20-day simple moving average (SMA20), while that difference is up 18.50% for SMA50 and it goes to 49.48% higher than SMA200.
Fulcrum Therapeutics Inc (NASDAQ: FULC) currently have 53.98M outstanding shares and institutions hold larger chunk of about 85.60% of that.
The stock has a current market capitalization of $343.31M and its 3Y-monthly beta is at 2.42. It has posted earnings per share of -$0.07 in the same period. It has Quick Ratio of 28.71 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FULC, volatility over the week remained 2.82% while standing at 3.15% over the month.
Stock’s fiscal year EPS is expected to drop by -630.36% while it is estimated to decrease by -1.22% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on May 23, 2025 offering an Outperform rating for the stock and assigned a target price of $12 to it. Coverage by Cantor Fitzgerald stated Fulcrum Therapeutics Inc (FULC) stock as an Overweight in their note to investors on May 15, 2025, suggesting a price target of $10 for the stock. Stock get a Sector perform rating from RBC Capital Mkts on September 12, 2024.
